Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC Sept 2021 | Findings from ATLANTIS: lurbinectedin/doxorubicin vs topotecan or CAV in SCLC

Laura Bonanno, MD, Istituto Oncologico Veneto, Padova, Italy, comments on the results of ATLANTIS, a Phase III trial comparing lurbinectedin/doxorubicin versus standard treatment with cyclophosphamide, doxorubicin and vincristine (CAV) or topotecan in patients with small cell lung cancer (SCLC) who have progressed on one prior line of platinum-based chemotherapy (NCT02566993). Whilst the primary endpoint of overall survival (OS) was not met, the addition of lurbinectedin improved tolerability and could therefore be used in treatment combinations to improve the quality of life (QoL) of patients with SCLC. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.